Pirates' Paul Skenes sets MLB record with dominant shutout performance
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.
Pirates' Paul Skenes sets MLB record with dominant shutout performance
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.